HGEN - Humanigen begins underwritten offering of 5M shares

Humanigen (HGEN) has started an underwritten public offering of 5M shares of common stock.Underwriters have a 30-day option to purchase up to an additional 750K shares.Jefferies, Credit Suisse, and Cantor are joint book-runners.Humanigen says it plans to use the proceeds from the offering for the manufacturing and commercial preparation of COVID-19 candidate lenzilumab should it receive FDA Emergency Use Authorization.Humanigen released phase 3 study results today showing lenzilumab met its primary endpoint.Humanigen shares are down 1.1% to $21.38 after closing the day up 54.5%.

For further details see:

Humanigen begins underwritten offering of 5M shares